catalyst calendar
← Catalyst calendar

TYRA biotech catalysts & pipeline

TYRA BIOSCIENCES INC · Data as of 2026-10-25

Upcoming catalysts

oral dabogratinib — Initial data

Q1 2027

Initial results from the safety sentinel cohort, including 6-month annualized height velocity and safety data from all five dose levels, are expected to be reported at the end of the first quarter of 2027, which will include an aggregate of approximately 25 children.
Source filing

oral dabogratinib — Initial data

2027

The Company is currently dosing and enrolling patients in SURF303, with initial results expected in 2027.
Source filing

Explore the free biotech catalyst calendar